| Latest Nephros News Headlines | | Date | Time | Source | | | 11/20/2008 | 4:18PM | PRNUS | Nephros Provides Corporate Update
NEW YORK, Nov. 20 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today provided an update on its operations and strategy.
Recent Highlights and Events
-- Appointed... More...>> |
| 11/14/2008 | 5:00PM | PRNUS | Nephros Reports Third Quarter 2008 Financial Results
NEW YORK, Nov. 14 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP) announced today unaudited financial results for the three and nine month periods ended September 30, 2008.
Financial Performance for the Quarter Ended September 30, 2008:
For the quarter ended September 30, 2008, Nephros reported net product revenues... More...>> |
| 09/18/2008 | 4:00PM | PRNUS | Nephros Receives Non-Compliance Notification from AMEX
NEW YORK, Sept. 18 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP) today announced that the Company has received notice from the staff of the American Stock Exchange (AMEX) indicating that the Company is not in compliance with certain conditions of the continued listing standards of Section 1003 of the AMEX Company... More...>> |
| 09/17/2008 | 8:31AM | PRNUS | Nephros Appoints James S. Scibetta as Chairman of Board of Directors
NEW YORK, Sept. 17 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), a medical device company focused on developing advanced filtration products for ESRD therapy and water purification, announced today that Mr. James S. Scibetta was appointed to serve as Chairman of its Board of Directors. Mr. Scibetta is a highly... More...>> |
| 09/17/2008 | 8:30AM | PRNUS | Nephros Appoints Ernest A. Elgin III as President and Chief Executive Officer
NEW YORK, Sept. 17 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP) today announced that, effective September 15, 2008, Ernest A. Elgin III has been appointed President and Chief Executive Officer.
Mr. Elgin joins the company from Novaflux Technologies, Inc., where he served as Chief Operating Officer.
"Ernie has... More...>> |
| 08/14/2008 | 9:12AM | PRNUS | Nephros Reports Second Quarter 2008 Financial Results
NEW YORK, Aug. 14 /PRNewswire-FirstCall/ -- Nephros, Inc.
(AMEX:NEP) announced today financial results for the three and six month periods ended June 30, 2008.
For the quarter ended June 30, 2008, Nephros reported net product revenues of $253,000, attributable to sales of its OLpur MD190 and MD220 products in Europe... More...>> |
| 07/14/2008 | 9:00AM | PRNUS | Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd
Company's DSU Products offer biologically safer water through point-of-use ultrafiltration
NEW YORK, July 14 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), a medical device company, announced today that it will be exhibiting its Dual Stage Ultrafilter products at the American Society for Healthcare Engineering... More...>> |
| 06/06/2008 | 9:00AM | PRNUS | Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
NEW YORK, June 6 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), a medical device company, announced today that it has completed the pivotal U.S. clinical trial for its OLpur(TM) H2H module and OLpur(TM) MD220 filter for End Stage Renal Disease (ESRD) therapy.
"We're excited and pleased to have reached this important... More...>> |
| 05/15/2008 | 3:48PM | PRNUS | Nephros Reports 2008 First Quarter Financial Results
NEW YORK, May 15 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP) announced today financial results for the three month period ended March 31, 2008.
Recent Highlights
-- Increased product revenues by 31% to $387,000.
-- Completed enrollment in the pivotal U.S. trial for the OLpur(TM)
H2H(TM) Hemodiafiltration... More...>> |
| 05/13/2008 | 4:23PM | PRNUS | Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008
Company Management to discuss the benefits of Hemodiafiltration therapy and Quality of Life for End-Stage Renal Disease Patients
NEW YORK, May 13 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), a medical device company developing and marketing products designed to improve the quality of life for the End-Stage Renal... More...>> |
| 04/29/2008 | 7:09PM | PRNUS | Nephros Appoints Gerald J. Kochanski as Chief Financial Officer
NEW YORK, April 29 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP) today announced that, effective April 28, 2008, Gerald J. Kochanski has been appointed Chief Financial Officer.
Mr. Kochanski joins the company from Lordi Consulting LLC, where he has served as Director since 2007.
"Jerry has a proven track record... More...>> |
| 04/21/2008 | 8:30AM | PRNUS | Nephros Strengthens Commercialization Team with Addition of Marketing Executive
NEW YORK, April 21 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), a medical device company specializing in the treatment of end-stage renal disease, today announced that it has named Joleen C. Turner to be Vice President of Marketing and Business Development, effective today.
In this role, Ms. Turner, an experienced... More...>> |
| 12/06/2006 | 8:00AM | PRNUS | Italian Clinical Study Demonstrates Nephros' Mid-Dilution HDF Therapy As Optimal Treatment for Patients with Limited Vascular Ac
Dr. Renaux Presented Clinical Study Results at American Society of Nephrology's Renal Week 2006
NEW YORK, Dec. 6 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), announced today the results of a clinical study conducted at the Maggiore Hospital in Lodi, Italy, by Jean Louis Renaux, PhD, Director of Scientific Affairs... More...>> |
| 11/20/2006 | 8:00AM | PRNUS | American Stock Exchange Will Continue Nephros's Listing
NEW YORK, Nov. 20 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP) today announced that the staff of the American Stock Exchange (AMEX) has reviewed the Company's plan of compliance to meet the AMEX's continued listing standards and will continue the Company's listing while the Company seeks to regain compliance with... More...>> |
| 11/15/2006 | 8:00AM | PRNUS | Nephros Reports Third Quarter 2006 Financial Results
NEW YORK, Nov. 15 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP) announced today financial results for the three months and nine months ended September 30, 2006.
For the quarter ended September 30, 2006, Nephros reported net revenue of $164,699, attributable to sales of its OLpur(TM) MDHDF products in Europe, compared... More...>> |
| 10/23/2006 | 8:00AM | PRNUS | Multi-Center Study Concludes Nephros Mid-Dilution Hemodiafiltration Therapy Achieves Higher Clearance of Low Molecular Weight Pr
Study Abstract Selected by Peer-Review Experts for Presentation at American Society of Nephrology (ASN) Congress
NEW YORK, Oct. 23 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), announced today that the results of a randomized, multi-site scientific study indicate that the Company's Mid-Dilution Hemodiafiltration... More...>> |
| 10/05/2006 | 8:00AM | PRNUS | Nephros Announces Positive Results of Clinical Study for Olpur MD190 Mid-Dilution Hemodiafiltration Filter
Study Findings to be Presented at October Nephrology Congress in Madrid
NEW YORK, Oct. 5 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), announced the positive results of a recent pilot clinical study confirming that the Company's proprietary end stage renal disease ("ESRD") therapy, Mid- Dilution Hemodiafiltration... More...>> |
| 10/04/2006 | 8:00AM | PRNUS | Nephros Selected for Development of Dual Stage Ultra Reliable Portable Personal Water Filtration by U.S. Marine Corps ATD
$1 Million Department of Defense Appropriation Approved
NEW YORK, Oct. 4 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), announced today that it will be working with the United States Marine Corps Warfighting Laboratory in Quantico, Va. to develop a portable personal water purification system following the approval... More...>> |
| 08/22/2006 | 5:27PM | PRNUS | Nephros Announces Restatement of Financial Statements
NEW YORK, Aug. 22 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP), today announced that the management, Board of Directors and Audit Committee of the Board of Directors of the Company concluded that the previously reported financial statements covering the period ended March 31, 2006 should no longer be relied upon... More...>> |
| 08/17/2006 | 4:30PM | PRNUS | Nephros Receives Extension to Submit AMEX Plan of Compliance
NEW YORK, Aug. 17 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX:NEP) today announced that the American Stock Exchange (AMEX) has granted the Company a one week extension, until August 24, 2006, to submit a plan of compliance advising the AMEX of the action the Company has taken, or will take, that would bring it into... More...>> |
|